Not available
Quote | Assembly Biosciences Inc. (NASDAQ:ASMB)
Last: | $15.13 |
---|---|
Change Percent: | -1.43% |
Open: | $15.205 |
Close: | $15.13 |
High: | $15.45 |
Low: | $14.82 |
Volume: | 6,677 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | Assembly Biosciences Inc. (NASDAQ:ASMB)
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
Message Board Posts | Assembly Biosciences Inc. (NASDAQ:ASMB)
Subject | By | Source | When |
---|---|---|---|
ASBM abandons HBV arena, for all practical purposes: | DewDiligence | investorshub | 04/18/2023 5:57:44 PM |
ASBM 4Q22 results12/31/22 cash=$92M(down_from $109M @9/30/22): | DewDiligence | investorshub | 03/22/2023 9:18:31 PM |
ASMB halts development of ABI-H3733, an HBV core inhibitor: | DewDiligence | investorshub | 03/22/2023 9:17:28 PM |
ASMB(+14%)reports_interim phase1/1b data_for HBV core inhibitors: | DewDiligence | investorshub | 12/19/2022 2:52:01 PM |
whytestocks: $ASMB News Article - Assembly Biosciences Doses First Subject in Phase 1a Clinical Tria | whytestocks | investorshangout | 11/14/2022 6:10:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...